Limits...
A novel combretastatin A-4 derivative, AC7700, strongly stanches tumour blood flow and inhibits growth of tumours developing in various tissues and organs.

Hori K, Saito S, Kubota K - Br. J. Cancer (2002)

Bottom Line: The change in tumour blood flow and the therapeutic effect of AC7700 on microtumours were observed directly by using Sato lung carcinoma implanted in a rat transparent chamber.In every tumour, tumour blood flow began to decrease immediately after AC7700 administration and reached a minimum at approximately 30 min after injection.These results demonstrate that AC7700 is effective for tumours growing in various tissues and organs and for metastases.

View Article: PubMed Central - PubMed

Affiliation: Department of Vascular Biology, Division of Cancer Control, Institute of Development, Aging and Cancer, Tohoku University, 4-1 Seiryomachi, Aoba-ku, Sendai 980-8575, Japan. k-hori@idac.tohoku.ac.jp

Show MeSH

Related in: MedlinePlus

Typical finding of growth inhibition caused by AC7700 in an SLC microtumour developing in a transparent chamber. (A) before administration of 10 mg kg−1 AC7700 administration; (B) 3.5 h after administration of AC7700; (C) 25 h later; (D) 48 h later; (E) histology 48 h later. Tumour blood flow completely stopped at 1 h after a single i.v. administration of AC7700. The whole region of the tumour, with a diameter of 2.5 mm, became necrotic. Tumours stopped growing completely during the 48-h observation period. Histological study (E and F, H&E stained) certified the tumour (shown on the right side) as necrotic. Original magnification: A–D, ×20; E, ×200; F, ×400. Bars: A–D, 500 μm; E, 100 μm; F, 50 μm.
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC2746587&req=5

fig8: Typical finding of growth inhibition caused by AC7700 in an SLC microtumour developing in a transparent chamber. (A) before administration of 10 mg kg−1 AC7700 administration; (B) 3.5 h after administration of AC7700; (C) 25 h later; (D) 48 h later; (E) histology 48 h later. Tumour blood flow completely stopped at 1 h after a single i.v. administration of AC7700. The whole region of the tumour, with a diameter of 2.5 mm, became necrotic. Tumours stopped growing completely during the 48-h observation period. Histological study (E and F, H&E stained) certified the tumour (shown on the right side) as necrotic. Original magnification: A–D, ×20; E, ×200; F, ×400. Bars: A–D, 500 μm; E, 100 μm; F, 50 μm.

Mentions: Inhibition of SLC tumour growth caused by AC7700 in the tumour developing in a transparent chamber. Tumour size at the start of observation was defined as 100%. During the 48 h after a single i.v. administration of 10 mg kg−1 AC7700, tumour size did not change at all (solid circle) (n=4). In contrast, tumours in the control group continued to grow (open circle) (n=4). Tumour area doubling time was 41.7±11.4 h.


A novel combretastatin A-4 derivative, AC7700, strongly stanches tumour blood flow and inhibits growth of tumours developing in various tissues and organs.

Hori K, Saito S, Kubota K - Br. J. Cancer (2002)

Typical finding of growth inhibition caused by AC7700 in an SLC microtumour developing in a transparent chamber. (A) before administration of 10 mg kg−1 AC7700 administration; (B) 3.5 h after administration of AC7700; (C) 25 h later; (D) 48 h later; (E) histology 48 h later. Tumour blood flow completely stopped at 1 h after a single i.v. administration of AC7700. The whole region of the tumour, with a diameter of 2.5 mm, became necrotic. Tumours stopped growing completely during the 48-h observation period. Histological study (E and F, H&E stained) certified the tumour (shown on the right side) as necrotic. Original magnification: A–D, ×20; E, ×200; F, ×400. Bars: A–D, 500 μm; E, 100 μm; F, 50 μm.
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC2746587&req=5

fig8: Typical finding of growth inhibition caused by AC7700 in an SLC microtumour developing in a transparent chamber. (A) before administration of 10 mg kg−1 AC7700 administration; (B) 3.5 h after administration of AC7700; (C) 25 h later; (D) 48 h later; (E) histology 48 h later. Tumour blood flow completely stopped at 1 h after a single i.v. administration of AC7700. The whole region of the tumour, with a diameter of 2.5 mm, became necrotic. Tumours stopped growing completely during the 48-h observation period. Histological study (E and F, H&E stained) certified the tumour (shown on the right side) as necrotic. Original magnification: A–D, ×20; E, ×200; F, ×400. Bars: A–D, 500 μm; E, 100 μm; F, 50 μm.
Mentions: Inhibition of SLC tumour growth caused by AC7700 in the tumour developing in a transparent chamber. Tumour size at the start of observation was defined as 100%. During the 48 h after a single i.v. administration of 10 mg kg−1 AC7700, tumour size did not change at all (solid circle) (n=4). In contrast, tumours in the control group continued to grow (open circle) (n=4). Tumour area doubling time was 41.7±11.4 h.

Bottom Line: The change in tumour blood flow and the therapeutic effect of AC7700 on microtumours were observed directly by using Sato lung carcinoma implanted in a rat transparent chamber.In every tumour, tumour blood flow began to decrease immediately after AC7700 administration and reached a minimum at approximately 30 min after injection.These results demonstrate that AC7700 is effective for tumours growing in various tissues and organs and for metastases.

View Article: PubMed Central - PubMed

Affiliation: Department of Vascular Biology, Division of Cancer Control, Institute of Development, Aging and Cancer, Tohoku University, 4-1 Seiryomachi, Aoba-ku, Sendai 980-8575, Japan. k-hori@idac.tohoku.ac.jp

Show MeSH
Related in: MedlinePlus